February 13th 2025
A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and biotech ahead.
HEOR requires executive leaders who have both scientific and managerial acumen.
February 11th 2025
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.
February 7th 2025
New technology is creating new opportunities but is also causing new complications.
January 30th 2025
In early phase trials innovative designs offer potential for improvements in efficiency and decision-making.
Why Now Could Be the Right Time to Reconsider Your Planning For Europe Strategy
Emma Thorp and Mel Walker, PhD, of RBW consulting discuss European strategy for US biotechs.
Bringing Global Hope to the Rare Disease Space
With a strong pharma background that includes bringing non-US biotechs stateside in the rare diseases space, Rami Levin, CEO of Saniona, talks about the importance of growing his company’s business and his dedication to that mission.
Biopharma’s Role in Transforming the Oncology Marketplace
Biopharma must step up amidst growing oncology market.
Branding Takes on a New Look
Pharma moves beyond promoting products to increase recognition of company names.
The Age of Influence
Pandemic lockdowns push pharma into brand-new era of social engagement.
Breaking Orbit
How pharmaceutical leaders at established companies can still disrupt the status quo and change the game.
Understanding the HCP: Patient-Level Data Proves Valuable
Evaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.
5 Lessons Learned from Embracing Agile in Commercial Launch
Agile methodologies provide an alternative to hierarchical, siloed and sequential way of managing activities and have the potential to dramatically reduce set-up time for new business or digital capabilities.
Orchestrating a Life Sciences Ecosystem Where Everyone is an A-Player: Insights with Landmark Bio’s Ran Zheng
Landmark Bio CEO Ran Zheng talks about the value of collaborating with best-in-class partners.
Optimizing the Value of Real-World Evidence Projects
Mark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.
How GxP Leaders Can Assess and Approach a Company’s Quality Culture
Using the interview process to ensure high organizational standards.
Startup Launch Guide: Avoiding 10 Common Pain Points
With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.
Making the Most of the Rising Biopharma M&As
Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.
Purposeful Partnerships for Post-COVID Era
Pharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.
Digital Transformation: A Journey, Not Just a Destination
Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.
SPACs: From Fad to Fixture: COVID Sparks Greater Use of IPO Alternative
The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing Needs
NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.
Uncover Potential Life Cycle Opportunities in Oncology Using Patient-Centric Outcomes
Focusing on prevention, diagnosis, treatment, and care monitoring during the patient journey in oncology to create value for stakeholders.
The Amazon Effect: A Data-Fueled Customer Experience
What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.
Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime Value
Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
Bridging the Generational Chasm in Oncology
How engaging with digital influencers holds the key for medical affairs.
Bringing Biosimilars to Market in Europe
If the life sciences sector can support healthcare professionals to gain confidence in substituting original treatments with new biosimilars, prices will reduce and patient outcomes will be enhanced.
How Just-in-Time Data Can Clear the Path to First Drug Launch
Implementing an efficient means of unifying disparate data and allowing teams to utilize this single source of truth data will allow them to track KPIs more effectively and get key insights when they need them.
Critical Connection: Patient Services and Product Launch
A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Mastering the Transition From Academia to Industry
Tips for rounding out the rough edges in crossover.
Injecting Traditional Scientific Exchange with New Life
Female medical affairs leaders speak out with unique perspectives on how MSLs can provide greater value to opinion leaders.
Commercial Sustainability of Pharmaceutical Innovations for Pandemics
Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Best Practices for Balancing Medical Affairs Globalization with Local Requirements
Addressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.
Manage Risk Effectively to Improve the Value of Your Alliance
In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Planning Ahead for a Post COVID-19 Workforce and Workplace
Dr. George Westerman talks to Michael Wong about how smarter executives will successfully lead their workforces in a post COVID-19 business environment.